Stock Events

Stock Events

Pharming Group N.V. 

$16.62
346
-$0.3-1.77% Thursday 20:00

Statistics

Day High
16.94
Day Low
15.74
52W High
21.34
52W Low
7.5
Volume
41,579
Avg. Volume
28,681
Mkt Cap
10.74B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.02
-0.01
-0
0.01
Expected EPS
0.00065
Actual EPS
N/A

Financials

-2.9%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
441.92MRevenue
-12.82MNet Income

Analyst Ratings

$39.00Average Price Target
The highest estimate is 41.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHAR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap13.58B
CSL Behring competes in the plasma-derived and recombinant therapeutic products space, similar to Pharming's focus on protein replacement therapies.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company has a strong presence in the rare diseases market, directly competing with Pharming's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Pharming's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other rare diseases, presenting competition in the rare disease market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in the biotechnology field focusing on rare diseases among other areas, making it a competitor in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing and marketing products for rare diseases, among other areas, competing with Pharming.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diverse portfolio including treatments for rare diseases, competing with Pharming in various therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the pharmaceutical and biotech industry.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on rare diseases, multiple sclerosis, and oncology, among others, competing with Pharming in the rare disease space.

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Show more...
CEO
Dr. Sijmen de Vries M.B.A., M.D.
Employees
404
Country
NL
ISIN
US71716E1055

Listings

F
DE
PHG.F
XETRA
DE
PHGN.XETRA
AS
NL
PHARM.AS
OTC Link
US
PHGUF

0 Comments

Share your thoughts

FAQ

What is Pharming Group N.V. stock price today?▼
The current price of PHAR is $16.62 USD — it has decreased by -1.77% in the past 24 hours. Watch Pharming Group N.V. stock price performance more closely on the chart.
What is Pharming Group N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharming Group N.V. stocks are traded under the ticker PHAR.
Is Pharming Group N.V. stock price growing?▼
PHAR stock has risen by +1.9% compared to the previous week, the month change is a +7.92% rise, over the last year Pharming Group N.V. has showed a +117.25% increase.
What is Pharming Group N.V. market cap?▼
Today Pharming Group N.V. has the market capitalization of 10.74B
When is the next Pharming Group N.V. earnings date?▼
Pharming Group N.V. is going to release the next earnings report on May 07, 2026.
What were Pharming Group N.V. earnings last quarter?▼
PHAR earnings for the last quarter are 0.01 USD per share, whereas the estimation was 0 USD resulting in a +366.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pharming Group N.V. revenue for the last year?▼
Pharming Group N.V. revenue for the last year amounts to 441.92M USD.
What is Pharming Group N.V. net income for the last year?▼
PHAR net income for the last year is -12.82M USD.
How many employees does Pharming Group N.V. have?▼
As of April 03, 2026, the company has 404 employees.
In which sector is Pharming Group N.V. located?▼
Pharming Group N.V. operates in the Health Care sector.
When did Pharming Group N.V. complete a stock split?▼
The last stock split for Pharming Group N.V. was on October 15, 2013 with a ratio of 1:1000.
Where is Pharming Group N.V. headquartered?▼
Pharming Group N.V. is headquartered in Leiden, NL.